Summarized by Masters of Longevity from PR Newswire.
A news article about an international clinical study of an investigational oral Alzheimer's therapy, previewing trial design and collaborative research focus.
Key Takeaways
- The randomized double-blind Phase 2 trial will enroll about 210 participants with early Alzheimer's disease.
- Participants will receive daily TML-6 100 mg, TML-6 200 mg, or placebo for 52 weeks with CDR-SB as primary endpoint.
- Blood biomarkers p‑Tau217, Aβ, GFAP, and NfL and imaging analyses will be included as secondary outcomes.
